Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
PTAFR Biologics Sequence Review Report 2026: Platelet-activating factor receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTAFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OR1F1 Biologics Sequence Review Report 2026: Olfactory receptor 1F1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OR1F1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OXTR Biologics Sequence Review Report 2026: Oxytocin receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OXTR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OR2A4 Biologics Sequence Review Report 2026: Olfactory receptor 2A4 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OR2A4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OPRL1 Biologics Sequence Review Report 2026: Nociceptin receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OPRL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OR1D2 Biologics Sequence Review Report 2026: Olfactory receptor 1D2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OR1D2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OPRM1 Biologics Sequence Review Report 2026: Mu-type opioid receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OPRM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OPRK1 Biologics Sequence Review Report 2026: Kappa-type opioid receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OPRK1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OPRD1 Biologics Sequence Review Report 2026: Delta-type opioid receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OPRD1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NTSR1 Biologics Sequence Review Report 2026: Neurotensin receptor type 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NTSR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NPY4R Biologics Sequence Review Report 2026: Neuropeptide Y receptor type 4 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NPY4R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
NPY2R Biologics Sequence Review Report 2026: Neuropeptide Y receptor type 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NPY2R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
208
209
210
211
212
>>
1872
>